Matthew L Bootsma
Overview
Explore the profile of Matthew L Bootsma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
38
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sharifi M, Feng E, Rydzewski N, Taylor A, Sperger J, Shi Y, et al.
Mol Oncol
. 2025 Feb;
PMID: 39985777
Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease. Several studies have identified transcriptional subtypes of mCRPC, but comprehensive analysis of prognostic gene expression pathways has been limited. Therefore, we...
2.
Sharifi M, Sperger J, Taylor A, Tippins K, Reese S, Carreno V, et al.
Cancer Discov
. 2025 Feb;
PMID: 39912912
The development of treatment resistance remains universal for patients with metastatic prostate cancer, driven by AR alterations and lineage state transitions. Identifying the evolution of lineage transitions in treatment resistance...
3.
Bakhtiar H, Sharifi M, Helzer K, Shi Y, Bootsma M, Shang T, et al.
NPJ Precis Oncol
. 2024 Oct;
8(1):220.
PMID: 39358429
In preclinical studies, p53 loss of function impacts chemotherapy response, but this has not been consistently validated clinically. We trained a TP53-loss phenocopy gene expression signature from pan-cancer clinical samples...
4.
Sharifi M, Shi Y, Chrostek M, Callahan S, Shang T, Berg T, et al.
JCI Insight
. 2024 Sep;
9(18).
PMID: 39315546
Therapies against cell-surface targets (CSTs) represent an emerging treatment class in solid malignancies. However, high-throughput investigations of CST expression across cancer types have been reliant on data sets of mostly...
5.
Rydzewski N, Shi Y, Li C, Chrostek M, Bakhtiar H, Helzer K, et al.
Commun Biol
. 2024 Mar;
7(1):314.
PMID: 38480799
Histopathologic diagnosis and classification of cancer plays a critical role in guiding treatment. Advances in next-generation sequencing have ushered in new complementary molecular frameworks. However, existing approaches do not independently...
6.
Bakhtiar H, Helzer K, Park Y, Chen Y, Rydzewski N, Bootsma M, et al.
NPJ Genom Med
. 2022 Oct;
7(1):58.
PMID: 36253482
DNA mutations in specific genes can confer preferential benefit from drugs targeting those genes. However, other molecular perturbations can "phenocopy" pathogenic mutations, but would not be identified using standard clinical...
7.
Rydzewski N, Peterson E, Lang J, Yu M, Chang S, Sjostrom M, et al.
NPJ Genom Med
. 2021 Sep;
6(1):76.
PMID: 34548481
We are now in an era of molecular medicine, where specific DNA alterations can be used to identify patients who will respond to specific drugs. However, there are only a...
8.
Bootsma M, Miller L, Sass G, Euclide P, Larson W
Evol Appl
. 2021 Apr;
14(4):1124-1144.
PMID: 33897825
Stocking of fish is an important tool for maintaining fisheries but can also significantly alter population genetic structure and erode the portfolio of within-species diversity that is important for promoting...
9.
Bootsma M, Gruenthal K, McKinney G, Simmons L, Miller L, Sass G, et al.
Mol Ecol Resour
. 2020 Jul;
20(6):1706-1722.
PMID: 32668508
Targeted amplicon sequencing methods, such as genotyping-in-thousands by sequencing (GT-seq), facilitate rapid, accurate, and cost-effective analysis of hundreds of genetic loci in thousands of individuals. Development of GT-seq panels is...